So the mechanisms of CCND1 gene amplification, posttranscriptional or posttranslational modifications, rearrangements, and variant polymorphisms can lead to abnormal protein levels and result in risk of cancer.[15–18] The common guanine-to-adenine polymorphism at nucleotide position 870 of the CCND1 gene is known to modulate the frequency of alternate splicing and presumably reduce transcript levels.[19]. Here, CCND1 is linked to cancer.